# Relatlimab + nivolumab

Source: https://onco.cc/drugs/relatlimab-nivolumab/  
OnCo record `relatlimab-nivolumab` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Opdualag combines relatlimab, the first drug targeting the LAG-3 immune brake, with nivolumab for melanoma.

## Summary

Opdualag is a fixed-dose combination of relatlimab, an antibody against the LAG-3 checkpoint, and nivolumab, an anti-PD-1 antibody, given as one infusion of nivolumab 480 mg with relatlimab 160 mg every 4 weeks. Because LAG-3 and PD-1 sit on the same exhausted T cells, releasing both brakes at once restores T-cell function more fully than PD-1 blockade alone. In RELATIVITY-047, in untreated advanced melanoma, progression-free survival was 10.1 versus 4.6 months compared with nivolumab alone, with less toxicity than ipilimumab-nivolumab. It was approved in 2022 in the US for unresectable or metastatic melanoma in patients aged 12 and over, the first LAG-3 therapy, and in the EU for PD-L1-negative melanoma. Fatigue, rash, thyroid dysfunction and adrenal insufficiency occur, and myocarditis is rare but monitored. Adjuvant and other tumour trials are ongoing.

## Fields

- Kind: Treatment
- Status: approved
- Last checked: 2026-09-04
- Brand: Opdualag
- Modality: Fixed-dose bispecific combination (anti-LAG-3 + anti-PD-1)
- Mechanism: Anti-LAG-3 plus anti-PD-1 in one infusion.
- Approvals: US 2022: Unresectable or metastatic melanoma, age ≥12; EU 2022: Melanoma, PD-L1 <1% restriction
- Dosing: IV infusion; Nivolumab 480 mg + relatlimab 160 mg every 4 weeks (≥40 kg)

## Sources

- Wikipedia: https://en.wikipedia.org/wiki/Nivolumab/relatlimab
- FDA label (DailyMed): https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Relatlimab

## Connected records

- cancers: [Advanced melanoma (unresectable stage III and stage IV)](https://onco.cc/cancers/advanced-melanoma/), [BRAF V600-mutant melanoma](https://onco.cc/cancers/braf-v600-melanoma/), [Melanoma](https://onco.cc/cancers/melanoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- targets: [FGL1](https://onco.cc/targets/fgl1/), [LAG-3](https://onco.cc/targets/lag3/), [PD-1](https://onco.cc/targets/pd1/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- trials: [A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors](https://onco.cc/trials/nct05970497/), [A Study of Subcutaneous Nivolumab + Relatlimab Fixed-dose Combination (FDC) in Previously Untreated Metastatic or Unresectable Melanoma](https://onco.cc/trials/nct05625399/), [A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed](https://onco.cc/trials/nct06101134/), [A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)](https://onco.cc/trials/nct06246916/), [RELATIVITY-047](https://onco.cc/trials/relativity-047/), [RELATIVITY-098](https://onco.cc/trials/relativity-098/), [VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]](https://onco.cc/trials/nct06264180/)
- pairings: [Caution: LAG-3 blockade outside active disease](https://onco.cc/pairings/lag3-adjuvant-caution/)
- pathways: [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/), [T-cell exhaustion](https://onco.cc/pathways/t-cell-exhaustion/)
- roadmaps: [Immunotherapy roadmap: Coley's toxins → checkpoint inhibitors → engineered immunity](https://onco.cc/roadmaps/immunotherapy-roadmap/)
- people: [Hussein A. Tawbi](https://onco.cc/people/hussein-tawbi/)
- key papers: [CheckMate 067 at ten years: nivolumab plus ipilimumab produces long-term survival in half of patients with advanced melanoma](https://onco.cc/key-papers/paper-checkmate-067-10-year-nejm-2025/), [RELATIVITY-047: relatlimab plus nivolumab, the first LAG-3 checkpoint combination, in untreated advanced melanoma](https://onco.cc/key-papers/paper-relativity-047-nejm-2022/)
- institutions: [Istituto Nazionale Tumori IRCCS Fondazione G. Pascale](https://onco.cc/institutions/pascale-naples/), [UPMC Hillman Cancer Center](https://onco.cc/institutions/upmc-hillman/)

---
JSON: https://onco.cc/api/v1/entities/relatlimab-nivolumab.json